(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride Chemical Properties

storage temp. 

2-8°C

solubility 

DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 10 mg/ml

form 

A crystalline solid

color 

White to yellow

Appearance

yellow-brown powder

InChIKey

JYRTWGCWUBURGU-XIMRXPCLNA-N

SMILES

C([C@@H]1C[C@@H](O)CN1C(=O)[C@@H](N)C(C)(C)C)(=O)NCC1C=CC(C2=C(N=CS2)C)=CC=1.Cl |&1:1,3,9,r|

Safety Information

HS Code 

2934100090

(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride Usage And Synthesis

Description

VHL ligand 1 is a building block in the synthesis of proteolysis-targeting chimera technologies (PROTACs). It is the von Hippel-Lindau (VHL) E3 ligase binding portion of some VHL-based PROTACs, including BET PROTAC MZ1 (Item No. 21622).

Uses

(2S,4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide Hydrochloride acts as a reagent in the synthesis of PROTAC compounds that mediated the degration of oncogenic c-ABL and BCR-ABL.

Uses

(S,R,S)-AHPC (HCl salt) is a ligand used in the recruitment of the von Hippel-Lindau (VHL) protein for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This (S,R,S) conformation is the active variant, and (S,S,S) is the inactive derivative (cat#901487) used as a negative control.

reaction suitability

reagent type: ligand

Synthesis

Step 4: Synthesis of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (ULM-1) To a stirred solution of tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate (12 g, 22.61 mmol) in dioxane (20 mL) at room temperature was added to a dioxane solution of hydrogen chloride (4N, 80 mL). The reaction mixture was stirred at room temperature for 2 h. LC-MS monitoring showed formation of the target product. The precipitated solid was collected by filtration to give ULM-1 in 48% yield as a yellow solid. 1H NMR (400 MHz, CD3OD): δ 9.84-9.82 (s, 1H), 7.58-7.54 (m, 4H), 4.71-4.41 (m, 4H), 4.13-4.08 (m, 1H), 3.86-3.71 (m, 2H), 3.36 (s, 1H), 2.60-2.58 (s, 3H), 2.35-2.07 (m, 2H), 1.19-1.12 (m, 9H). LC-MS (ES+): m/z 431.11 [MH+], tR = 0.73 min (run time 2.0 min).

IC 50

VHL

References

[1] Patent: WO2016/118666, 2016, A1. Location in patent: Paragraph 0398; 0399; 0411; 0412
[2] Patent: US2017/8904, 2017, A1. Location in patent: Paragraph 0376; 0382
[3] Patent: US2017/281784, 2017, A1. Location in patent: Paragraph 0191; 0197
[4] Patent: US2018/125821, 2018, A1
[5] Patent: WO2014/108452, 2014, A1. Location in patent: Page/Page column 50

(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride(1448189-80-7)Related Product Information

• Cereblon Ligand 1
• 4-Hydroxy ThalidoMide
• Protein degrader 1 (TFA)
• 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione
• L-Prolinamide, 3-methyl-L-valyl-4-hydroxy-N-[(1S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-, (4R)-